Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
July 25, 2023 08:30 ET
|
Avenue Therapeutics
MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
October 03, 2022 08:00 ET
|
Fortress Biotech, Inc.
MIAMI, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”)...